Recombinant Human CCL22 293 Cell Lysate
- Gene Information
- Related Products
|Description :||Antigen standard for chemokine (C-C motif) ligand 22 (CCL22) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.|
|Source :||HEK 293 cells|
|Components :||This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).|
|Size :||0.1 mg|
|Storage Instruction :||Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.|
|Applications :||ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.|
|Gene Name :||CCL22 chemokine (C-C motif) ligand 22 [ Homo sapiens ]|
|Official Symbol :||CCL22|
|Synonyms :||CCL22; chemokine (C-C motif) ligand 22; SCYA22, small inducible cytokine subfamily A (Cys Cys), member 22; C-C motif chemokine 22; A 152E5.1; ABCD 1; DC/B CK; MDC; MGC34554; STCP 1; MDC(1-69); CC chemokine STCP-1; macrophage-derived chemokine; small inducible cytokine A22; small-inducible cytokine A22; stimulated T cell chemotactic protein 1; stimulated T-cell chemotactic protein 1; small inducible cytokine subfamily A (Cys-Cys), member 22; ABCD-1; SCYA22; STCP-1; DC/B-CK; A-152E5.1;|
|Gene ID :||6367|
|mRNA Refseq :||NM_002990|
|Protein Refseq :||NP_002981|
|UniProt ID :||O00626|
|Chromosome Location :||16q13|
|Pathway :||Chemokine receptors bind chemokines, organism-specific biosystem; Chemokine signaling pathway, organism-specific biosystem; Chemokine signaling pathway, conserved biosystem; Class A/1 (Rhodopsin-like receptors), organism-specific biosystem; Cytokine-cytokine receptor interaction, organism-specific biosystem; Cytokine-cytokine receptor interaction, conserved biosystem; GPCR ligand binding, organism-specific biosystem;|
|Function :||chemokine activity;|
|◆ Recombinant Protein|
|Ccl22-2034M||Recombinant Mouse Ccl22 Protein, Myc/DDK-tagged||+Inquiry|
|CCL22-0627H||Recombinant Human CCL22 Protein, GST-Tagged||+Inquiry|
|CCL22-311H||Recombinant Human CCL22 Protein, His-tagged||+Inquiry|
|CCL22-2887M||Active Recombinant Mouse Ccl22 Protein||+Inquiry|
|CCL22-1108P||Recombinant Pig CCL22 Protein, His-tagged||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
The expression of CCL22 gene is regulated by a variety of signaling pathways, including inflammatory factor-mediated signaling pathways, cytokine-mediated signaling pathways, and transcription factors.
Studies have shown that by interfering with the interaction of the CCL22 protein and its receptor CCR4, tumor growth, improve inflammatory response, and regulate autoimmune diseases can be inhibited. These findings provide potential application value for the development of corresponding therapeutic strategies.
A number of inhibitors or antagonists that interact with CCL22 proteins have been developed that block the binding of CCL22 to its receptor CCR4, thereby interfering with its biological function.
The mechanism of action of CCL22 protein in specific diseases can be studied through cell culture experiments, animal models, clinical samples, and related biochemical techniques.
There are complex interactions between CCL22 proteins and other chemokines. They may influence the migration and localization of immune cells by competing for receptors, mutual regulation of expression, etc.
Some studies have shown that in tumor immunotherapy, inhibiting the expression of CCL22 or interfering with its interaction with CCR4 can enhance the effect of immunotherapy and improve the survival rate of patients.
Customer Reviews (3)Write a review
The catalytic activity of CCL22 is very strong, which can significantly improve the selectivity and yield of chemical reactions, and has high application value. -
This repeatability of CCL22 is very good, which can ensure the safety of the experiment and avoid unnecessary risks. -
CCL22 were well suited for our research needs due to their simple storage conditions and long-term preservation. -
Ask a Question for All CCL22 Products
Required fields are marked with *
My Review for All CCL22 Products
Required fields are marked with *